ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

belumosudil

Also written as “Belumosudil”, “Belumosudil (KD025)” and “Belumosudil mesylate”.

Its studies are mostly in Bronchiolitis Obliterans Syndrome · Immune System Diseases · Scleroderma, Diffuse · Autoimmune Diseases · Psoriasis, led by 2 companies.

Drug pageBelumosudil: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 24, 202426 company-led studies, 6 open or runningNext primary completion: Jan 26, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi256 open or runningphase 4since Sep 24, 2024Apr 2, 2014Jan 26, 2027phase 1 · NCT07726914
BioNova Pharmaceuticals (Shanghai)its history only10 open or runningphase 2since Jun 11, 2021Jun 11, 2021none ahead

Also a collaborator on its studies: Meiji Seika Pharma and Quotient Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Apr 2, 2014.

  1. Nov 13, 2019Phase 1 study in Hepatic ImpairmentNCT04166942 · 35 enrolled · United States
  2. Jun 9, 2020Named belumosudilINNProposed as its International Nonproprietary Name in WHO's List 123 · before, KD025
  3. Dec 11, 2020Phase 2 study in Scleroderma, DiffuseNCT04680975 · 10 enrolled · United States
  4. Jan 13, 2021Early phase 1 study in Healthy VolunteersNCT04735822 · 30 enrolled · United Kingdom
  5. Feb 2, 2022Phase 2 study in Bronchiolitis Obliterans SyndromeNCT05305989 · 23 enrolled · United States
  6. Oct 3, 2022Phase 2 study in Bronchiolitis Obliterans SyndromeNCT05567406
  7. Jun 15, 20233 phase 1 studies in Immune System DiseasesNCT05918627, NCT05918614, NCT05918588
  8. Oct 7, 2023Phase 3 study in Lung Transplant RejectionNCT06082037 · 180 planned · United States, Australia, Austria and more
  9. Nov 16, 2023Phase 3 study in Bronchiolitis Obliterans SyndromeNCT06143891 · 260 enrolled · United States, Argentina, Australia and more
  10. Sep 24, 2024Phase 4 study in Bronchiolitis Obliterans SyndromeNCT06616415 · 6 enrolled · China
  11. Jul 25, 2025Phase 2 study in Bronchiolitis Obliterans SyndromeNCT07116031 · 37 planned · United States, Belgium, Canada and more
  12. Aug 14, 2025Phase 4 study in Bronchiolitis Obliterans SyndromeNCT07135973 · 26 planned
  13. Jul 21, 2026Phase 1 study in Bronchiolitis Obliterans SyndromeNCT07726914 · 58 planned
  14. Aug 4, 2026Phase 3 study in Bronchiolitis Obliterans SyndromeNCT07771439 · 356 planned · Netherlands, Spain
  15. Nov 10, 2026Primary completion moved from 2026-09-28 to 2027-01-26Date moved laterphase 1 · +4 months · NCT07726914

Ahead

  1. Jan 26, 2027Primary completion: phase 1 study in Bronchiolitis Obliterans SyndromeNCT07726914
  2. Aug 30, 2027Primary completion: phase 4 study in Bronchiolitis Obliterans SyndromeNCT07135973
  3. Sep 25, 2028Primary completion: phase 2 study in Bronchiolitis Obliterans SyndromeNCT07116031
  4. Sep 29, 2028Primary completion: phase 3 study in Bronchiolitis Obliterans SyndromeNCT06143891

TargetBeta

ROCK1 →ROCK2 →read by rule
“An orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), ”NCIt, by rule
“Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
netarsudilruleAlconphase 420

Studies

All 25 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07771439Bronchiolitis Obliterans Syndrome · Netherlands, Spain3RecruitingSep 14, 2029356
NCT07726914Bronchiolitis Obliterans Syndrome1Not yet recruitingJan 26, 202758
NCT07135973Bronchiolitis Obliterans Syndrome4Not yet recruitingAug 30, 202726
NCT07116031Bronchiolitis Obliterans Syndrome · United States, Belgium, Canada and more2RecruitingSep 25, 202837
NCT06616415Bronchiolitis Obliterans Syndrome · China4CompletedMay 12, 20266
NCT06143891Bronchiolitis Obliterans Syndrome · United States, Argentina, Australia and more3Active, not recruitingSep 29, 2028260
NCT06082037Lung Transplant Rejection · United States, Australia, Austria and more3RecruitingJan 29, 2029180
NCT05918627Immune System Diseases · United States1CompletedDec 9, 200932
NCT05918614Immune System Diseases · United States1CompletedJun 7, 20148
NCT05918588Immune System Diseases · United States1CompletedMar 6, 201432
NCT05567406Bronchiolitis Obliterans Syndrome2WithdrawnAug 31, 20260
NCT05305989Bronchiolitis Obliterans Syndrome · United States2CompletedJun 6, 202423
NCT04735822Healthy Volunteers · United KingdomEarly 1CompletedSep 3, 202130
NCT04680975Scleroderma, Diffuse · United States2TerminatedMay 10, 202210
NCT04166942Hepatic Impairment · United States1CompletedJun 6, 202235
NCT03907540Autoimmune Diseases · United Kingdom1CompletedMay 20, 20195
NCT03919799Scleroderma, Diffuse · United States2TerminatedAug 9, 202236
NCT03640481Bronchiolitis Obliterans Syndrome · United States2TerminatedDec 11, 2023159
NCT03530995Autoimmune Diseases · United Kingdom1CompletedFeb 8, 201973
NCT02852967Skin Diseases · United States2CompletedFeb 13, 2019110
NCT02841995Graft vs Host Disease · United States2CompletedMay 12, 202254
NCT02688647Idiopathic Pulmonary Fibrosis · United States2CompletedApr 13, 202176
NCT02557139Bioavailability · United Kingdom1CompletedOct 12, 201523
NCT02317627Psoriasis Vulgaris · United States2CompletedMar 201638
NCT02106195Psoriasis Vulgaris · United States2CompletedSep 20148

How it is read

Names in the registry

  • “Belumosudil”, 15 entries
  • “Belumosudil (KD025)”, 3 entries
  • “Belumosudil mesylate”, 3 entries
  • “KD025”, 2 entries
  • “Belumosudil 200 mg QD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.